Phase II trial of coltuximab ravtansine in combination with anticancer agents in patients with B-cell malignancies
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Coltuximab ravtansine (Primary) ; Antineoplastics
- Indications B cell lymphoma
- Focus Therapeutic Use
- 29 Apr 2016 According to an ImmunoGen media release, this trial is expected to initiate in first half of 2017.
- 10 Jan 2016 According to an ImmunoGen media release, company is planning to initiate this trial in the mid year of 2016.
- 05 Aug 2015 New trial record